Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: Results from the KNOW-CKD

Lee, Changhyun; Park, Sun-Hee; Chang, Tae-Ik; Kang, Ea Wha; Nam, Ki Heon; Joo, Young Su; Sung, Suah; Kim, Yeong Hoon; Chae, Dong‐Wan; Park, Su Kyung; Ahn, Curie; Oh, Kook‐Hwan; Yoo, Tae‐Hyun; Kang, Shin‐Wook; Han, Seung Hyeok

doi:10.1016/j.numecd.2021.09.037

Cited by 16 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14 Lee et al found a proportional relationship between LDL cholesterol levels and adverse cardiovascular outcomes in CKD patients, with the lowest risk observed in those with LDL-C levels below 70 mg/dl, suggesting the appropriateness of setting a lower LDL-C target for managing cardiovascular risk in this population. 15 Studies by Palazhy et al and Sujatha et al observed hyperlipidemia in CRF patients, while Mikolasevic et al reported dyslipidemia across various groups including those not requiring dialysis, individuals with nephrotic range proteinuria, ESRD patients, and renal transplant recipients. [16][17][18] Shah et al demonstrated that elevated serum triglyceride (TG) levels independently predict negative renal outcomes in non-dialysis requiring CKD patients, influenced by factors such as age, estimated glomerular filtration rate (eGFR), and albuminuria.…”

Section: Discussionmentioning

confidence: 98%

Examining the relationship between chronic kidney disease, dyslipidaemia, and dysglycemia: a prospective study

Ghosh,

Dutta,

Kayet

2024

Int J Res Med Sci

View full text Add to dashboard Cite

Background: Chronic kidney disease (CKD) results in profound lipid disorders, which stem largely from dysregulation of high-density lipoproteins (HDL) and triglyceride-rich lipoprotein metabolism. Objectives were to evaluate the correlation between chronic kidney disease, dyslipidaemia and dysglycemia. Methods: In-patient and outpatient department (OPD) of department of medicine, COM and JNM Hospital, Kalyani. Cases are defined as patients (>20 years of age) with a diagnosis of CKD (non-oedematous). The controls are defined as age and gender-matched patients (>20 years) attending medicine OPD/indoor without diagnosis of CKD. Results: Among the CKD cases, 30 individuals were diagnosed as overtly diabetic, whereas in the control group, 22 participants had fasting blood sugar (FBS) levels equal to or exceeding 126 mg/dl. The mean FBS was 111 mg/dl (standard deviation (SD) 44 mg/dl) in the CKD group and 91 mg/dl (SD 31 mg/dl) in the control group. The difference in FBS levels between the CKD patients' group and the control group was statistically significant (p value=0.001). Conclusions: Hyperglycaemia is also significantly associated with CKD in form of increased fasting blood sugar (47% among cases as compared to 30% in control) and increased post-prandial blood sugar (49% in cases as compared to 36% in controls). Dyslipidaemia occurs in CKD cases (39% among CKD cases and in 24% of controls) in the form of increased triglycerides (TG), LDL and low HDL.

show abstract

Section: Discussionmentioning

confidence: 98%

Examining the relationship between chronic kidney disease, dyslipidaemia, and dysglycemia: a prospective study

Ghosh,

Dutta,

Kayet

2024

Int J Res Med Sci

View full text Add to dashboard Cite

show abstract

“…Гипотезу о липонефротоксичности подтверждают не только экспериментальные данные, но и результаты клинических исследований. Например, в исследовании KNOW-CKD у 1886 пациентов с ХБП 1-5 стадии риск комбинированной почечной конечной точки (снижение СКФ по крайней мере на 50% или развитие терминальной хронической почечной недостаточности) в течение в среднем около 5 лет у пациентов с уровнем холестерина ЛНП ≥130 мг/дл был в два раза выше, чем у пациентов с уровнем холестерина ЛНП <70 мг/дл (отношение рисков 2,05; 95% доверительный интервал 1, 56) [54].…”

Section: дислипидемияunclassified

Nephrotic syndrome: treatment and prevention of complications

Moiseev,

Bobkova,

Chebotareva

et al. 2024

CPT

View full text Add to dashboard Cite

Nephrotic syndrom (NS) that frequently occurs in patients with various glomerular disease can cause serious and even life-threatening complications including diuretic-resistant oedema, hypovolemic shock, venous and arterial thromboembolism, and infections. Moreover, high proteinuria and dyslipidemia in patients with NS may contribute to progression of chronic kidney disease. The authors review treatment of NS and prevention of its complications.

show abstract

“…For instance, elevated LDL-C levels seem to be associated with the risk of CKD progression [ 15 ]. In the analysis of 1,886 patients with CKD stages 1 to pre-dialysis 5, the risk of composite kidney event (defined as a composite of 50% decline in eGFR during follow-up or onset of end-stage kidney disease including initiation of dialysis or kidney transplantation) was highest in those with LDL-C ≥130 mg/dL (HR, 2.05; 95% CI, 1.19 to 3.56) compared to those with LDL-C <70 mg/dL during the median follow-up of 5.2 years [ 15 ]. Hypertriglyceridemia is also associated with the progression of CKD [ 16 ].…”

Section: Dyslipidemia and Ckd Progressionmentioning

confidence: 99%

“…On top of the characteristic alterations in the lipid profile among the patients with CKD [ 2 - 4 , 12 ], the impact of dyslipidemia on cardiovascular outcomes seems to be substantially modified by deteriorating kidney function [ 13 , 14 ]. Most importantly, accumulating evidence strongly suggests the association between dyslipidemia and the risk of CKD progression [ 15 - 17 ].…”

Section: Introductionmentioning

confidence: 99%

Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview

Suh

Kim

2023

Diabetes Metab J

View full text Add to dashboard Cite

Dyslipidemia is a potentially modifiable cardiovascular risk factor. Whereas the recommendations for the treatment target of dyslipidemia in the general population are being more and more rigorous, the 2013 Kidney Disease: Improving Global Outcomes clinical practice guideline for lipid management in chronic kidney disease (CKD) presented a relatively conservative approach with respect to the indication of lipid lowering therapy and therapeutic monitoring among the patients with CKD. This may be largely attributed to the lack of high-quality evidence derived from CKD population, among whom the overall feature of dyslipidemia is considerably distinctive to that of general population. In this review article, we cover the characteristic features of dyslipidemia and impact of dyslipidemia on cardiovascular outcomes in patients with CKD. We also review the current evidence on lipid lowering therapy to modify the risk of cardiovascular events in this population. We finally discuss the association between dyslipidemia and CKD progression and the potential strategy to delay the progression of CKD in relation to lipid lowering therapy.

show abstract

Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: Results from the KNOW-CKD

Cited by 16 publications

References 42 publications

Examining the relationship between chronic kidney disease, dyslipidaemia, and dysglycemia: a prospective study

Examining the relationship between chronic kidney disease, dyslipidaemia, and dysglycemia: a prospective study

Nephrotic syndrome: treatment and prevention of complications

Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview

Contact Info

Product

Resources

About